MDA — Medical Device Authority, Malaysia
Medical devices in Malaysia are regulated by the Medical Device Authority (MDA) under the Ministry of Health, pursuant to the Medical Device Act 2012 (Act 737) and its supporting regulations. The framework closely mirrors international risk-based classification systems, dividing devices into Class A (lowest risk) through Class D (highest risk).
All medical devices — including IVDs and active devices — intended for supply or use in Malaysia must be registered in the Medical Device Authority (MDA) system before placement on the market. Registration requires a local Authorized Representative (AR) who is a registered entity in Malaysia or a company with a valid establishment licence under the Act.
The submission is made through the Medical Device Information and Communication System (MeDC@St), the MDA's online portal. Dossier requirements follow ASEAN Common Submission Dossier Template (CSDT) standards for most device classes. Class C and D devices require significantly more extensive technical documentation, including clinical evidence, risk management files, and manufacturing quality system (QMS) data.
- Medical Device Act 2012 (Act 737) — primary legislation
- Authorized Representative or locally registered entity required
- MeDC@St portal for all submission, renewal, and variation filings
- ASEAN CSDT-aligned dossier requirements for Class B–D
- Post-market vigilance reporting obligations apply to all registered devices
MDA Review Timelines by Device Class
Estimated MDA processing times from submission acceptance. Timelines exclude deficiency response periods and may vary.
Integrated Services for Malaysia MDA Registration
MDA Device Registration
Complete registration management for Class A–D devices via the MeDC@St portal — including ASEAN CSDT dossier preparation, establishment licence coordination, deficiency response management, and approval tracking. We manage the full submission lifecycle from classification to certificate issuance.
Authorized Representative Services
JNPMEDI APAC provides Authorized Representative (AR) services in Malaysia — acting as your locally accountable representative with MDA. Structurally independent of your commercial distribution arrangement, the AR relationship ensures regulatory accountability without locking you into a specific commercial partner.
Post-Market & Compliance
Ongoing post-market obligations under the Medical Device Act 2012 — vigilance reporting, field safety corrective actions, registration renewals, variation submissions, and regulatory intelligence monitoring for changes affecting your registered devices in Malaysia.
Why JNPMEDI APAC for Malaysia MDA Registration
JNPMEDI APAC operates directly in Malaysia — not through a subcontracted local agent. This means your dossiers are managed by the same team that oversees your Singapore and APAC regulatory strategy, with full accountability and a single point of contact across markets.
Your Authorized Representative should never be your distributor. When the AR and the distributor are the same entity, changing your commercial partner means a regulatory transfer — a costly, time-consuming process. JNPMEDI APAC keeps these roles structurally separate, protecting your commercial freedom.
Most manufacturers entering Malaysia are already registered or planning registration in Singapore. JNPMEDI APAC coordinates both markets simultaneously — maximizing document reuse, aligning submission timelines, and reducing the total regulatory burden across your APAC rollout.
Malaysia MDA Registration — FAQ
Yes. An Authorized Representative is required under the Medical Device Act 2012. Foreign manufacturers cannot register directly with MDA — a locally accountable AR must be named in the registration. JNPMEDI APAC serves as your Malaysia AR, removing the need to establish your own subsidiary at the outset.
The ASEAN Common Submission Dossier Template (CSDT) is a standardized technical dossier format adopted by ASEAN member states including Malaysia. Preparing your dossier to the ASEAN CSDT format means the core documentation can be reused across multiple Southeast Asian markets — reducing duplication when registering in Malaysia, Singapore, Indonesia, Vietnam, and Thailand simultaneously.
MDA Class C devices typically take 140–150 days from submission acceptance. This excludes any deficiency response period — which can add 30–60 days depending on the complexity of queries raised. JNPMEDI APAC manages the full submission cycle to minimize delays and respond to MDA queries efficiently.
Yes. JNPMEDI APAC coordinates both Malaysia MDA and Singapore HSA registrations under a single contract, maximizing document reuse across the ASEAN CSDT framework. This eliminates the need to manage two separate regulatory partners and allows submission timelines to be aligned for the most efficient market entry.